Heparin administration in coronary angiography

Evaluation of heparin administration effects during diagnostic coronary angiography in coronary artery disease for active bleeding, hematoma, pseudoanuerysm and ischemic accidents

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202199080N1

Enrollment

500

Registered

2012-03-15

Start date

2006-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic heart disease. Atherosclerotic heart disease

Interventions

Intervention 1: heparin administration during coronary angiography in Atherosclerotic heart disease (3000 unit/IV). Intervention 2: No administration of Heparin in control group.

Treatment - Drugs

heparin administration during coronary angiography in Atherosclerotic heart disease (3000 unit/IV)

No administration of Heparin in control group

Sponsors

Hamadan university of medical sciences

Lead Sponsor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: all patients with CAD referred to Ekbatan hospital for coronary angiography. Exclusion criteria: patients with severe AS, PVD, coagulopathy and angiography procedures more than 30 minutes.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hematoma, active bleeding. Timepoint: until 30 days after angiography. Method of measurement: inspection and clinical evaluation.	—

Secondary

Measure	Time frame
Cerebrovascualr accident. Timepoint: until 30 days after angiography. Method of measurement: inspection and clinical evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen GHarakhani

Hamadan university of medical sciences

gharakhani@umsha.ac.ir+98 81 1825 1245

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026